200,000+ products from a single source!
sales@angenechem.com
202914-18-9 | Acetamide, 2-[(2,3-dihydro-1H-inden-2-yl)amino]-, hydrochloride (1:1)
CAS No: 202914-18-9 Catalog No: AG0028JT MDL No:
Product Description
Catalog Number:
AG0028JT
Chemical Name:
Acetamide, 2-[(2,3-dihydro-1H-inden-2-yl)amino]-, hydrochloride (1:1)
CAS Number:
202914-18-9
Molecular Formula:
C11H15ClN2O
Molecular Weight:
226.7026
IUPAC Name:
2-(2,3-dihydro-1H-inden-2-ylamino)acetamide;hydrochloride
InChI:
InChI=1S/C11H14N2O.ClH/c12-11(14)7-13-10-5-8-3-1-2-4-9(8)6-10;/h1-4,10,13H,5-7H2,(H2,12,14);1H
InChI Key:
JPNNIRXUJSPGRM-UHFFFAOYSA-N
SMILES:
NC(=O)CNC1Cc2c(C1)cccc2.Cl
EC Number:
606-503-7
UNII:
YHA48V735B
Properties
Complexity:
203
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
2
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
226.087g/mol
Formal Charge:
0
Heavy Atom Count:
15
Hydrogen Bond Acceptor Count:
2
Hydrogen Bond Donor Count:
3
Isotope Atom Count:
0
Molecular Weight:
226.704g/mol
Monoisotopic Mass:
226.087g/mol
Rotatable Bond Count:
3
Topological Polar Surface Area:
55.1A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
Literature
| Title | Journal |
|---|---|
| Indantadol, a novel NMDA antagonist and nonselective MAO inhibitor for the potential treatment of neuropathic pain. | IDrugs : the investigational drugs journal 20070901 |
| CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model. | The journal of pain : official journal of the American Pain Society 20060801 |
| CHF3381, a novel antinociceptive agent, attenuates capsaicin-induced pain in rats. | European journal of pharmacology 20050920 |
| Mechanistic pharmacokinetic and pharmacodynamic modeling of CHF3381 (2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide monohydrochloride), a novel N-methyl-D-aspartate antagonist and monoamine oxidase-A inhibitor in healthy subjects. | The Journal of pharmacology and experimental therapeutics 20050501 |
| Steady-state pharmacokinetics and pharmacodynamics of CHF3381, a novel antineuropathic pain agent, in healthy subjects. | British journal of clinical pharmacology 20050401 |
| CHF 3381. | Drugs in R&D 20040101 |
| Antinociceptive activity of the N-methyl-D-aspartate receptor antagonist N-(2-Indanyl)-glycinamide hydrochloride (CHF3381) in experimental models of inflammatory and neuropathic pain. | The Journal of pharmacology and experimental therapeutics 20030801 |
| Mechanisms of action of CHF3381 in the forebrain. | British journal of pharmacology 20030801 |
| Safety, pharmacokinetics, and pharmacodynamics of CHF 3381, a novel N-methyl-D-aspartate antagonist, after single oral doses in healthy subjects. | Journal of clinical pharmacology 20030801 |
| Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist. | Neuroreport 20021115 |
| Anticonvulsant preclinical profile of CHF 3381: dopaminergic and glutamatergic mechanisms. | Pharmacology, biochemistry, and behavior 20010901 |
| Preclinical evaluation of CHF3381 as a novel antiepileptic agent. | Neuropharmacology 20010601 |
Related Products
© 2019 Angene International Limited. All rights Reserved.